Novo Nordisk A/S - Product Pipeline Review - 2016

Published: Mar, 2016 | Pages: 97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Novo Nordisk A/S - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Novo Nordisk A/S - Product Pipeline Review - 2016', provides an overview of the Novo Nordisk A/S's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Novo Nordisk A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Novo Nordisk A/S
- The report provides overview of Novo Nordisk A/S including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Novo Nordisk A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Novo Nordisk A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Novo Nordisk A/S's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Novo Nordisk A/S
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Novo Nordisk A/S's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Novo Nordisk A/S Snapshot 7
Novo Nordisk A/S Overview 7
Key Information 7
Key Facts 7
Novo Nordisk A/S - Research and Development Overview 8
Key Therapeutic Areas 8
Novo Nordisk A/S - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Novo Nordisk A/S - Pipeline Products Glance 16
Novo Nordisk A/S - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Novo Nordisk A/S - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Novo Nordisk A/S - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Novo Nordisk A/S - Drug Profiles 21
(insulin aspart + insulin degludec) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(insulin degludec + liraglutide) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
insulin degludec 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NN-1218 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
nonacog beta pegol 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NN-9535 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
somapacitan 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
turoctocog alfa pegol 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
liraglutide (recombinant) 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
liraglutide (recombinant) + NN-8828 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NN-9536 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NN-9709 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
OG-217SC 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
OI-338GT 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AM-833 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
concizumab 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
G-530L 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LAI-287 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
NN-1406 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NN-9747 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NN-9748 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
OI-320GT 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Insulin 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Synthetic Peptides to Agonize NMUR1 and NMUR2 for Obesity and Diabetes 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
XMet-A 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Novo Nordisk A/S - Pipeline Analysis 58
Novo Nordisk A/S - Pipeline Products by Target 58
Novo Nordisk A/S - Pipeline Products by Route of Administration 60
Novo Nordisk A/S - Pipeline Products by Molecule Type 61
Novo Nordisk A/S - Pipeline Products by Mechanism of Action 62
Novo Nordisk A/S - Recent Pipeline Updates 63
Novo Nordisk A/S - Discontinued Pipeline Products 85
Discontinued Pipeline Product Profiles 85
balaglitazone 85
coagulation factor XIII A-subunit (recombinant) 85
LAI-338 86
liraglutide (recombinant) 86
NN-1952 86
NN-1954 86
NN-1955 86
NN-1956 86
NN-1998 87
NN-7128 87
NN-7129 87
NN-8555 87
NN-8828 87
NN-9112 87
NN-9161 87
NN-9925 87
NNC126-0083 87
OG-217GT 88
OG-987GT 88
OG-987SC 88
ragaglitazar 88
semaglutide 88
tifenazoxide 88
vatreptacog alfa (activated) 88
Novo Nordisk A/S - Company Statement 89
Novo Nordisk A/S - Locations And Subsidiaries 91
Head Office 91
Other Locations & Subsidiaries 91
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 96
Disclaimer 97

List of Tables
Novo Nordisk A/S, Key Information 7
Novo Nordisk A/S, Key Facts 7
Novo Nordisk A/S - Pipeline by Indication, 2016 9
Novo Nordisk A/S - Pipeline by Stage of Development, 2016 11
Novo Nordisk A/S - Monotherapy Products in Pipeline, 2016 12
Novo Nordisk A/S - Combination Treatment Modalities in Pipeline, 2016 13
Novo Nordisk A/S - Partnered Products in Pipeline, 2016 14
Novo Nordisk A/S - Partnered Products/ Combination Treatment Modalities, 2016 15
Novo Nordisk A/S - Pre-Registration, 2016 16
Novo Nordisk A/S - Phase III, 2016 17
Novo Nordisk A/S - Phase II, 2016 18
Novo Nordisk A/S - Phase I, 2016 19
Novo Nordisk A/S - Preclinical, 2016 20
Novo Nordisk A/S - Pipeline by Target, 2016 58
Novo Nordisk A/S - Pipeline by Route of Administration, 2016 60
Novo Nordisk A/S - Pipeline by Molecule Type, 2016 61
Novo Nordisk A/S - Pipeline Products by Mechanism of Action, 2016 62
Novo Nordisk A/S - Recent Pipeline Updates, 2016 63
Novo Nordisk A/S - Discontinued Pipeline Products, 2016 85
Novo Nordisk A/S, Subsidiaries 91